COVID-19: etiology, clinical picture, treatment
Whereas the XX century marked the history of acute respiratory disease investigation as a period for generating in-depth system of combating influenza viruses (Articulavirales: Orthomyxoviridae, Alpha-/Betainfluenzavirus) (based on environmental and virological monitoring of influenza A virus in its natural reservoir — aquatic and semi-aquatic birds — to supervising epidemic influenza), a similar system is necessary to build up in the XXI century with regard to especially dangerous betacoronaviruses (Nidovirales: Coronaviridae, Betacoronavirus): Severe acute respiratory syndrome-related coronavirus (SARS-CoV) (subgenus Sarbecovirus), Severe acute respiratory syndrome-related coronavirus 2 (SARSCoV-2) (Sarbecovirus), Middle East respiratory syndrome-related coronavirus (MERS-CoV) (Merbecovirus). This became particularly evident after pandemic potential has been revealed in 2020 by the SARS-CoV-2. This review provides an insight into the historic timeline of discovering this virus, its current taxonomy, ecology, virion morphology, life cycle, molecular biology, pathogenesis and clinical picture of the etiologically related COVID-19 (Coronavirus disease 2019) as well as data available in the scientific literature on the anti-SARS-CoV-2-effectiveness of passive immunotherapy and most debated drugs used to treat COVID-19: Chloroquine, Hydroxychloroquine, Nitazoxanide, Ivermectin, Lopinavir and Ritonavir, Camostat mesilate, Remdesivir, Ribavirin, Tocilizumab, Anakinra, corticosteroids, and type I interferons. The pathogenesis of SARS-CoV-2 infection implicates decreased efficacy of artificial respiration, which, in this case might be replaced by more efficient extracorporeal membrane blood oxygenation supplemented with nitrogen oxide and/or Heliox inhalations..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Инфекция и иммунитет - 10(2020), 3, Seite 421-445 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
M. Yu. Shchelkanov [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
2019-ncov |
|---|
| doi: |
10.15789/2220-7619-CEC-1473 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ000780642 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ000780642 | ||
| 003 | DE-627 | ||
| 005 | 20230311013313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2020 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.15789/2220-7619-CEC-1473 |2 doi | |
| 035 | |a (DE-627)DOAJ000780642 | ||
| 035 | |a (DE-599)DOAJdfb3bda56b0144259aefb030bf7edde1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a M. Yu. Shchelkanov |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19: etiology, clinical picture, treatment |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Whereas the XX century marked the history of acute respiratory disease investigation as a period for generating in-depth system of combating influenza viruses (Articulavirales: Orthomyxoviridae, Alpha-/Betainfluenzavirus) (based on environmental and virological monitoring of influenza A virus in its natural reservoir — aquatic and semi-aquatic birds — to supervising epidemic influenza), a similar system is necessary to build up in the XXI century with regard to especially dangerous betacoronaviruses (Nidovirales: Coronaviridae, Betacoronavirus): Severe acute respiratory syndrome-related coronavirus (SARS-CoV) (subgenus Sarbecovirus), Severe acute respiratory syndrome-related coronavirus 2 (SARSCoV-2) (Sarbecovirus), Middle East respiratory syndrome-related coronavirus (MERS-CoV) (Merbecovirus). This became particularly evident after pandemic potential has been revealed in 2020 by the SARS-CoV-2. This review provides an insight into the historic timeline of discovering this virus, its current taxonomy, ecology, virion morphology, life cycle, molecular biology, pathogenesis and clinical picture of the etiologically related COVID-19 (Coronavirus disease 2019) as well as data available in the scientific literature on the anti-SARS-CoV-2-effectiveness of passive immunotherapy and most debated drugs used to treat COVID-19: Chloroquine, Hydroxychloroquine, Nitazoxanide, Ivermectin, Lopinavir and Ritonavir, Camostat mesilate, Remdesivir, Ribavirin, Tocilizumab, Anakinra, corticosteroids, and type I interferons. The pathogenesis of SARS-CoV-2 infection implicates decreased efficacy of artificial respiration, which, in this case might be replaced by more efficient extracorporeal membrane blood oxygenation supplemented with nitrogen oxide and/or Heliox inhalations. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a sars-cov-2 | |
| 650 | 4 | |a 2019-ncov | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a nidovirales | |
| 650 | 4 | |a coronaviridae | |
| 650 | 4 | |a betacoronavirus | |
| 650 | 4 | |a sarbecovirus | |
| 650 | 4 | |a clinical features | |
| 650 | 4 | |a pathogenesis | |
| 650 | 4 | |a treatment | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a L. V. Kolobukhina |e verfasserin |4 aut | |
| 700 | 0 | |a O. A. Burgasova |e verfasserin |4 aut | |
| 700 | 0 | |a I. S. Kruzhkova |e verfasserin |4 aut | |
| 700 | 0 | |a V. V. Maleev |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Инфекция и иммунитет |d Sankt-Peterburg : NIIÈM imeni Pastera, 2015 |g 10(2020), 3, Seite 421-445 |w (DE-627)DOAJ000085677 |x 23137398 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:3 |g pages:421-445 |
| 856 | 4 | 0 | |u https://doi.org/10.15789/2220-7619-CEC-1473 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/dfb3bda56b0144259aefb030bf7edde1 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.iimmun.ru/iimm/article/view/1473 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2220-7619 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2313-7398 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 3 |h 421-445 | ||